Scientists Are "Reolysin" The Power Of Live Biologics To Fight ancer In Two Recent Studies

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers

Traditional cancer treatments such as chemotherapy and radiotherapy come with a serious disadvantage: they cannot distinguish cancer cells from normal cells Since normal cells can be stunted by chemotherapy and destroyed by radiation along with abnormal cells, patients may experience serious health issues during a course of extended treatment

algary-based Oncolytics Biotech Inc has developed an innovative approach to cancer therapy that might help patients avoid such serious side effects Their strategy relies on one of the human body’s traditional foes: viruses Specifically, Oncolytics is testing a live cancer biologic called ROLYSIN®, which is derived from the human reovirus

“One of the distinguishing characteristics of the reovirus is its tendency to replicate within certain cancer cells, namely, those that possess a feature known as an activated Ras pathway,” said Brad Thompson, hairman, President and hief xecutive Officer of Oncolytics Biotech “Approximately two-thirds of all cancers involve cells that are Ras-activated ROLYSIN® appears to kill off these cancer cells by rupturing their walls, creating a chain reaction of ‘explosions’ that rip through tumors”

A team lead by Dr onica ita at the Institute of Drug Development IDD, the ancer Therapy and Research enter at the University of Texas Health Science enter UTHS in San Antonio, Texas, recently provided updated results from a Phase II study using ROLYSIN® in patients with sarcomas metastatic to the lung

The investigators reported that the treatment has been well-tolerated to date, and that 19 of 44 patients experienced stable disease ranging from 2 to 20 months, resulting in a total clinical benefit rate complete response partial response stable disease of 43% The response objective for the study was three or more patients having prolonged stabilization of disease >6 months or better, for the agent to be considered The trial exceeded its established objective with six patients experiencing stable disease for more than six months Two patients have experienced stable disease for more than 19 months One of these patients has synovial cell sarcoma that relapsed following surgery, while the other has wing’s Sarcoma and had previously progressed following multiple treatments

“We were very happy to participate in the study,” said Dr ita “ROLYSIN® is a promising option for patients with sarcoma, as shown by the results of this study As a single agent, the virus had a clinical benefit rate of 43% and it was very well-tolerated We are contemplating further studies combining ROLYSIN® with chemotherapy in order to integrate the virus in the panoply of agents used for sarcoma treatment”

New Progress on Head and Neck ancer

While the new viral treatment will not completely dispose of the need for chemotherapy, its ability to weaken and shrink tumors might restrict the amount of chemo that is required or help agents such as paclitaxel and carboplatin do their jobs

The company recently provided updated results from a Phase III UK trial RO 011 of ROLYSIN® combined with paclitaxelcarboplatin for patients with advanced cancers in a poster presentation at the 2009 AAR-NI-ORT olecular Targets and ancer Therapeutics conference in Boston The investigators reported that ROLYSIN® was well-tolerated when administered intravenously in combination with paclitaxel and carboplatin Of 19 evaluable patients with head and neck cancer, mostly SHN refractory to prior platinum-based chemotherapy for recurrentmetastatic disease, eight experienced partial responses and six had stable disease The total clinical benefit rate complete response partial response stable disease observed in head and neck cancer patients in the trial was 74% Of four patients with malignant melanoma on the trial, one experienced a partial response and one had stable disease

“A 42% response rate and a 74% clinical benefit rate in a platinum refractory patient population that typically has a poor prognosis and limited therapeutic options is very encouraging,” said Dr Thompson “These results further validate our decision to advance ROLYSIN® in combination with paclitaxel and carboplatin into a Phase III trial in this patient population”

Source
Oncolytics Biotech

source : www.medicalnewstoday.com

Related News:

• 600 Million-Year-Old Origins Of Vision Discovered By Scientists At UCSB
• MBL Scientists Identify Driving Forces In Human Cell Division
• Scientists’ Understanding Of Limb Growth Altered By Roving ‘Sonic Hedgehog’ Gene
• Scientists Shed New Light On How Retina’s Hardware Is Used In Color Vision
• Scientists Make Important Discovery In Gene Regulation
• Hormone Study Gives Scientists A Sense Of How Animals Bond
• Scientists Discover Clues To Human Diseases By Studying Dolphins In A Changing Ocean
• Scientists Discover Molecular Pathway For Organ Tissue Regeneration And Repair
• Scientists discover TB disease mechanism and molecule to block it
• Don’t forget to eat blueberries: Scientists find they help memory